Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vera Therapeutics (VERA)
NASDAQ:VERA
Vera Therapeutics (VERA) Stock Price & Analysis
199 Followers
VERA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.07 - $50.78
Previous Close$39.48
Volume307.51K
Average Volume (3M)1.42M
Market Cap
$2.09B
Enterprise Value$2.06B
Total Cash (Recent Filing)$160.72M
Total Debt (Recent Filing)$53.71M
Price to Earnings (P/E)-17.3
Beta0.71
Next Earnings
Jun 20, 2024EPS Estimate
-$0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.28
Shares Outstanding54,452,029
10 Day Avg. Volume1,613,539
30 Day Avg. Volume1,419,948
Standard Deviation0.38
R-Squared0.02
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)21.43
Price to Sales (P/S)1115.02
Price to Cash Flow (P/CF)-21.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.07K
Enterprise Value/Gross Profit1.07K
Enterprise Value/Ebitda-28.85
Forecast
1Y Price Target
$45.78Price Target Upside20.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Vera Therapeutics News
Bulls Say, Bears Say
Bulls Say
Acquisition ImpactVertex's acquisition of Alpine for approximately $4.9 billion in cash underscores the significant commercial potential of BLyS/APRIL inhibitors.
Analyst ExpectationAnalyst institutes a $60 price target based on a probability weighted NPV of peak atacicept sales in IgAN markets such as the US, EU, and Japan.
Clinical Trial SuccessInitial clinical data from the RUBY-3 study shows a significant reduction in proteinuria and stabilization of kidney function, suggesting strong efficacy of the treatment.
Bears Say
Clinical And Competitive RisksDownside risks include timeline setbacks for upcoming readouts due to enrolment hurdles, underwhelming clinical data from atacicept, and development of competitive molecules that reach the market prior to atacicept.
Financial PerformanceVERA reported a net loss of $96MM for the year-end, indicating financial challenges.
Potential Conflict Of InterestInvestors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VERA FAQ
What was Vera Therapeutics’s price range in the past 12 months?
Vera Therapeutics lowest stock price was $6.07 and its highest was $50.78 in the past 12 months.
What is Vera Therapeutics’s market cap?
Currently, no data Available
When is Vera Therapeutics’s upcoming earnings report date?
Vera Therapeutics’s upcoming earnings report date is Jun 20, 2024 which is in 56 days.
How were Vera Therapeutics’s earnings last quarter?
Vera Therapeutics released its earnings results on Mar 20, 2024. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.505 by -$0.035.
Is Vera Therapeutics overvalued?
According to Wall Street analysts Vera Therapeutics’s price is currently Undervalued.
Does Vera Therapeutics pay dividends?
Vera Therapeutics does not currently pay dividends.
What is Vera Therapeutics’s EPS estimate?
Vera Therapeutics’s EPS estimate is -$0.55.
How many shares outstanding does Vera Therapeutics have?
Vera Therapeutics has 54,916,817 shares outstanding.
What happened to Vera Therapeutics’s price movement after its last earnings report?
Vera Therapeutics reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.505. Following the earnings report the stock price went up 4.399%.
Which hedge fund is a major shareholder of Vera Therapeutics?
Among the largest hedge funds holding Vera Therapeutics’s share is Woodline Partners LP. It holds Vera Therapeutics’s shares valued at 39M.
---
Vera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.78 (20.47% Upside)
$45.78 (20.47% Upside)
Blogger Sentiment
Bullish
VERA Sentiment 71%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 54.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $33.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 10.3%
Last 30 Days ▼ 10.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
527.11%
12-Months-Change
Fundamentals
Return on Equity
-107.50%
Trailing 12-Months
Asset Growth
33.56%
Trailing 12-Months
Company Description
Vera Therapeutics
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
---
VERA Stock 12 Months Forecast
Average Price Target
$45.78
▲(20.47% Upside)
Technical Analysis
Best Analysts Covering VERA
1 Year
1 Year Success Rate
8/11 ratings generated profit
1 Year Average Return
+171.56%
reiterated a buy rating 3 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +171.56% per trade.
---